LY 320135
SIGMA/L5295 - ≥98% (HPLC)
Synonym: 4-
CAS Number: 176977-56-3
Empirical Formula (Hill Notation): C24H17NO4
Molecular Weight: 383.40
MDL Number: MFCD00945878
Linear Formula: C24H17NO4
Product Type: Chemical
| assay | ≥98% (HPLC) |
| color | orange |
| form | powder |
| InChI | 1S/C24H17NO4/c1-27-18-9-7 |
| InChI key | RYNSGDFWBJWWSZ-UHFFFAOYSA |
| originator | Eli Lilly |
| Quality Level | 100  |
| SMILES string | COc1ccc(cc1)-c2oc3cc(OC)c |
| solubility | DMSO: ≥10 mg/mL |
| storage temp. | 2-8°C |
| Biochem/physiol Actions: | LY320135 is a potent CB1 receptor antagonist/inverse agonist (Ki = 141 nM) with greater than 70-fold selectivity over CB2 receptors (Ki > 10 μM). |
| Biochem/physiol Actions: | LY320135 is a potent CB1 receptor antagonist/inverse agonist (Ki = 141 nM) with greater than 70-fold selectivity over CB2 receptors (Ki > 10 μM). Structurally dissimilar from SR 141716A and AM 251. Shows weak binding to both 5-HT2 (Ki = 6.4 μM) and muscarinic receptors (Ki = 2.1 μM) |
| Features and Benefits: | This compound is featured on the Cannabinoid Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here . |
| Features and Benefits: | This compound was developed by Eli Lilly . To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here . |
| Packaging: | 5, 25 mg in glass bottle |
| Symbol |  GHS06 |
| Signal word | Danger |
| Hazard statements | H301 |
| Precautionary statements | P301 + P310 |
| Hazard Codes | T |
| Risk Statements | 25 |
| Safety Statements | 45 |
| RIDADR | UN 2811 6.1 / PGIII |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥98% (HPLC) |
| Storage Temp. | 2-8°C |
| UNSPSC | 12352200 |